Join
Live feed
·
PRReleasevia Quantisnow
Larimar Therapeutics Inc. logo

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

ByQuantisnow·Wall Street's wire, on your screen.
LRMR· Larimar Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LRMR (Larimar Therapeutics Inc.) and more on Quantisnow.